Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02032888 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 238
- Enrollment target
NCT02032888 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 238 participants.
The verdict
NCT02032888, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 238 participants
- Enrollment target
Study Summary
A study of the efficacy and safety of the combination of daclatasvir and sofosbuvir in the treatment of hepatitis C virus and HIV coinfection.
Interventions
- DRUG Sofosbuvir
- DRUG Daclatasvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02032888
The ClinicalTrials.gov registry entry for NCT02032888 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sofosbuvir is the first listed.
NCT02032888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02032888 about?
NCT02032888 is a clinical study titled "A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.". A study of the efficacy and safety of the combination of daclatasvir and sofosbuvir in the treatment of hepatitis C virus and HIV coinfection.
What is the current status of trial NCT02032888?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 238 participants. The study started on 2014-02. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02032888?
The interventions under investigation include: Sofosbuvir (DRUG), Daclatasvir (DRUG).
Who is sponsoring clinical trial NCT02032888?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.